deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT05381506

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma (O-Gemox)

A Phase II, Prospective, Multicenter Study Ofrelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

Sponsor: Sun Yat-sen University

Conditions DLBCL
Interventions Orelabrutinib and Gemox
Updated 5 times since 2022 Last updated: Jul 5, 2022 Started: Jul 31, 2022 Primary completion: Dec 31, 2023 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on DLBCL, this trial is ongoing. The trial is conducted by Sun Yat-sen University and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2026 · 17 months · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 7 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Feb 2026 — Present [monthly]

    Unknown PHASE2

    Status: Not Yet Recruiting → Unknown

  2. Sep 2024 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

  5. Jun 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sun Yat-sen University
Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations